The companies said the merger has created a technology-driven leading CDMO and API manufacturer with the critical mass to support customers in the pharmaceutical and biotechnology sectors across the entire drug life cycle.

Sylke Hassel, former CEO of PharmaZell and CEO of the new group said: “This merger is a significant opportunity to further improve our offering, providing a broader set of technologies, a global manufacturing footprint and an end-to-end lifecycle management.”

The transaction was backed by PharmaZell’s majority shareholder Bridgepoint Group, which acquired the Raubling-based API producer in 2020.

Author: Elaine Burridge, Freelance Journalist